Low Risk TAVR: What the Data Tells Us (Michael J. Reardon, MD) March 26, 2020

The Treatment of Aortic Valve Disease in 2020, A Surgeon’s Perspective (Michael J. Reardon, MD)Подробнее

TAVR Data for the Surgeon (Michael Reardon, MD)Подробнее

TMVR - Hope or Hype (Michael J. Reardon, MD)Подробнее

TAVR and Valve-in-Valve (Michael Reardon, MD)Подробнее

Michael J Reardon, MD - TAVR in Asymptomatic or Moderate ASПодробнее

Michael J. Reardon, MD: Long-Term TAVR PlansПодробнее

TAVR: Optimizing the Choice of Prosthesis and Patient (MICHAEL J. REARDON, MD)Подробнее

Michael J. Reardon, MD: The TAVR Study for Low-Risk MortalityПодробнее

ACC 2019: Corevalve low-risk TAVR trial - Prof Michael J Reardon & Dr Nicolas van MieghemПодробнее

Which Low-Risk Patients Should Receive TAVR?Подробнее

Transcatheter Aortic Valve Replacement: Will Surgical AVR Disappear? (Michael Reardon, MD)Подробнее

AVR, Valve Types, TAVI (Michael J. Reardon, MD) Sunday, August 21, 2016Подробнее

TAVR Valves That Are Here and Valves That Are Coming (Michael Reardon, MD)Подробнее

TAVR-Device Selection & Expanding Indications/Percutaneous Alt. Access (Michael J. Reardon, MD)Подробнее

Bicuspid Valve Aortopathy: Surgical and Medical Considerations (Michael J. Reardon, MD)Подробнее

TAVR (Michael J. Reardon, MD) - April 6th, 2017 Re-Evolution SummitПодробнее

Michael J Reardon, MD on durability of TAVR in patients with aortic stenosis with Chadi Alraies, MDПодробнее

TAVR Horizons: Partner II, SurTAVI and Beyond (Michael J. Reardon, MD) April 30, 2016Подробнее

How Innovation Happens: Lessons from the Transcatheter Valve Trials (Michael Mack, MD) Nov. 14, 2019Подробнее